Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
← catalyst calendarNCT05836259 · readout ≤ 377 d
Sponsored by Tenaya Therapeutics (industry) · TNYA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
30estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-10 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypertrophic Cardiomyopathy
Intervention
- Genetic: TN-201
Primary outcomes
what the primary-completion date above is the date OFNumber and severity of Adverse Events over the course of the study.
measured 5 Years
Number of Serious Adverse Events related to study drug.
measured 5 Years
Publications
- PMID 39302117 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · TNYA's whole pipeline · Catalyst calendar · Every registered study · What changed